Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-12-27

FDA Approved: LATANOPROST — Supplemental Application (Bausch & Lomb Incorporated)

View source ↗

Summary

The FDA approved a supplemental application for latanoprost filed by Bausch & Lomb Incorporated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Latanoprost (Latanoprost)

Snippet

SUPPL AP for LATANOPROST (LATANOPROST)